BioSpace News Archive

Codexis, inc. announced two oral presentations highlighting its therapeutic discovery programs to develop potential treatments for homocystinuria and maple syrup urine disease at the 14th International Congress of Inborn Errors of Metabolism 2021, taking place from November 21 to November 24, 2021, in Sydney, Australia and virtually.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum.

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting virtually during a fireside chat at the Jefferies 2021 London Healthcare Conference being held November 16-19, 2021.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2021.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that CEO, Tim Dyer, will present at the H.C. Wainwright 7th Annual Israel Virtual Conference.

Geneva, Switzerland, November 15,2021 – Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed Phase 1 studies in Japan with JNJ-40411813.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that the U.S. Food and Drug Administration has set the Prescription Drug User Fee Act date for the New Drug Application for Maxigesic® IV on 30 June 2022.

The vendor landscape of the global reprocessed medical devices market is significantly consolidated with the leading few companies collectively accounting for a lion’s share in the overall market, observes Transparency Market Research in a recent report.

The global meningitis diagnostic testing market was valued over US$ 105.5 Mn in 2016 and is projected to register cumulative annual growth rate of over 3.0% from 2017 to 2025, according to a new report published by Transparency Market Research titled “Meningitis Diagnostic Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

The rise in world population, coupled with the increasing number of various chronic and acute diseases are the prime factors augmenting the health information exchange market.